Literature DB >> 6359869

Hematologic effects of antipyretic analgesics. Drug-induced agranulocytosis.

W F Heit.   

Abstract

Drug-induced agranulocytosis may be type I (involving the drug, antibodies and neutrophils), type II (associated with accumulated drug toxicity in hypersensitive persons), or type III (representing different etiologies induced by immune and toxic mechanisms). The pyrazolones (amidopyrine, dipyrone and butazones), phenothiazine derivatives, antithyroid drugs, and antibiotics are thought to be causative agents in agranulocytosis. The symptoms may involve sudden onset of high fever, sore throat with ulcerative angina, or stomatitis. Diagnosis of agranulocytosis is confirmed by severe granulocytopenia (0-0.5 X 10(9)/l), but bone marrow examination is required to rule out aplastic anemia and cancer. Treatment of drug-induced agranulocytosis involves immediate withdrawal of the incriminated drug. In most patients, granulocyte, reticulocyte, and thrombocyte cell counts overshoot in the regenerative phase of drug-induced agranulocytosis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6359869     DOI: 10.1016/0002-9343(83)90234-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

1.  Use of Neo-melubrina, a banned antipyretic drug, in San Diego, California: a survey of patients and providers.

Authors:  L Taylor; S Abarca; B Henry; L Friedman
Journal:  West J Med       Date:  2001-09

Review 2.  Pharmacological Management of Acute Endodontic Pain.

Authors:  Asma A Khan; Anibal Diogenes
Journal:  Drugs       Date:  2021-10-07       Impact factor: 9.546

3.  Adjunct dipyrone in association with oral morphine for cancer-related pain: the sooner the better.

Authors:  José F Duarte Souza; Paula P Lajolo; Hélio Pinczowski; Auro Del Giglio
Journal:  Support Care Cancer       Date:  2007-09-06       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.